Bosniak Classification (2019 Revision)
Select Cyst Characteristics
Assessment Pending
Select the CT/MRI imaging characteristics to determine the Bosniak category and malignancy risk.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
When to Use the Bosniak Classification
Incidental renal cyst discovered on CT or MRI (most common: 20–30% of adults > 50 years have at least one renal cyst)
Follow-up of known renal cyst to assess stability or change over time (Bosniak IIF requires surveillance imaging)
Pre-treatment planning for cystic renal mass (active surveillance vs ablation vs partial nephrectomy vs radical nephrectomy)
Characterization of complex cystic renal lesion seen on ultrasound (requires CT or MRI for definitive classification)
Pre-operative planning for nephron-sparing surgery (classification predicts malignancy probability and guides margin strategy)
Research inclusion criteria for renal mass protocols (standardized entry criteria based on Bosniak class)
Imaging Requirements for Accurate Classification (Critical Quality Indicators)
Bosniak classification requires dedicated renal mass protocol CT or MRI. CT requirements: Unenhanced phase (baseline HU), corticomedullary phase (30–40 sec delay, evaluates enhancement of solid components), nephrographic phase (90–120 sec delay, best for cyst characterization and septal assessment), excretory phase (5–10 min, optional, helps differentiate collecting system pseudolesion). Slice thickness ≤ 3 mm (1–1.5 mm preferred) for multiplanar reformats. MRI requirements: T1-weighted (in-phase and opposed-phase), T2-weighted, diffusion-weighted (DWI), and dynamic contrast-enhanced T1 with subtraction (to eliminate fat signal). Absolute requirement: Measurable enhancement defined as ≥ 15–20 HU increase on CT (from unenhanced to corticomedullary or nephrographic phase) or visible enhancement on subtracted MRI (increase > 20% on T1 post-contrast). Do not classify based on ultrasound alone (inadequate for septal and solid component assessment).
Pseudoenhancement — Common Diagnostic Pitfall
Pseudoenhancement is artifactual increase in cyst density (HU) on contrast-enhanced CT due to beam-hardening from adjacent high-attenuation renal parenchyma or iodine in collecting system. Can cause a simple cyst (Bosniak I) to appear as a hyperdense cyst (Bosniak II) or falsely suggest enhancement (Bosniak III–IV). Characteristic features: (1) Small cyst (< 1.5 cm diameter) in interpolar region surrounded by densely enhancing parenchyma, (2) Apparent enhancement of 10–25 HU (within pseudoenhancement range), (3) Symmetric increase across whole cyst (not focal), (4) No visible solid component. Prevention: Review unenhanced phase carefully; measure HU in same location in both phases using identical region-of-interest size and position; use dual-energy CT (iodine overlay maps differentiate true iodine uptake from artifact). If pseudoenhancement suspected, repeat with MRI (pseudoenhancement does not occur).
Key Definitions — Practical Application
| Term | Definition | Clinical Implication | Pitfall |
|---|---|---|---|
| Measurable enhancement | CT: ≥ 15–20 HU increase (unenhanced to contrast phases). MRI: visible enhancement on subtracted T1 images (increase > 20% signal intensity compared to unenhanced). | Pathognomonic for solid tissue (malignancy unless proven otherwise). Any enhancement in a septal or wall pushes to Bosniak III or IV. | Pseudoenhancement (false positive) or small cyst with respiratory motion misregistration (false negative). Use thin slices, breath-hold, and repeat ROI measurement. |
| Septum (septa) | Thin (< 1 mm) or thick (≥ 1 mm) linear or curvilinear structures traversing cyst lumen, best seen on nephrographic phase. Multiple septa create loculations. | Hairline-thin septa (Bosniak II). Smooth thick septa (≥ 1 mm) without enhancement (Bosniak IIF). Thick irregular or enhancing septa (Bosniak III–IV). | Artifact from volume averaging (bright edge of cyst wall simulating septum) — review orthogonal planes. |
| Calcification | Fine (punctate, non-measurable) or coarse (measurable, nodular, or eggshell). | Fine calcification (Bosniak II). Short segment of thick calcification without soft tissue (Bosniak II). Nodular or extensive thick calcification (Bosniak IIF). Calcification with enhancing soft tissue (Bosniak IV). | Calcification alone does NOT equal malignancy unless associated with solid enhancing soft tissue. |
| Wall | Margin of cyst; smooth thin (< 1 mm) vs smooth thick (≥ 1 mm) vs irregular/nodular. | Hairline thin wall (Bosniak I). Smooth thick wall without enhancement (Bosniak IIF). Irregular or nodular wall (Bosniak III–IV). | Wall measurement requires orthogonal views (tangential section can falsely thicken normal thin wall). |
| Solid component | Enhancing soft tissue within cyst lumen, independent of wall or septa. May be nodular, polypoid, or mass-like. | Any enhancing solid component = Bosniak IV (malignant until proven otherwise). | Differentiate from hemorrhagic clot (non-enhancing on all phases, may change on follow-up). |
| Homogeneous high attenuation | Cyst measuring > 20 HU on unenhanced CT (typically 40–90 HU) without enhancement and no solid component. | Bosniak II if < 3 cm and completely intrarenal (95% benign hemorrhagic or proteinaceous cyst). Bosniak IIF if ≥ 3 cm (requires follow-up, 5–10% malignancy risk). | Measure unenhanced HU carefully (exclude iodine from prior contrast — wait 6 weeks for washout). |
Related Scores in Practice
In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Renal Nephrometry Score or the Padua Prediction Score to formulate a comprehensive care plan.
Last Comprehensive Review: 2026